Breakthrough innovation specialist Cambridge Consultants has developed BacillAi, a concept system that harnesses Artificial Intelligence (AI) and standard, low-cost hardware to improve treatment monitoring of tuberculosis (TB) in resource-limited countries. With TB the second largest cause of death by infectious disease in the developing world, the BacillAi system is part of Cambridge Consultants’ continuing mission to move AI beyond the hype, addressing practical, high-impact challenges and improving lives on a global scale.
Using machine intelligence to achieve the seemingly impossible
TB’s high mortality rate is due to a variety of factors, including a lack of available, affordable diagnosis and inconsistent results acquired in patient follow-up. TB is monitored by taking a sputum sample and manually counting cells under a microscope. In low-resource countries, this is very difficult. There are few skilled staff working in difficult conditions. Clinicians may need to review ten patients per day, while for each patient they may need to count hundreds of cells through a microscope. This leads to eye strain for clinicians and poor quality, slow results for patients.
BacillAi is an end-to-end concept system that uses a smartphone to capture images from an ordinary laboratory microscope. Stained sputum sample images are analyzed using a deep learning algorithm, specifically a convolutional neural network, to identify, count and classify TB cells, in order to determine the disease state of the patient. The results of the test are returned to the clinician via a dedicated app. An automated system to count cells and classify treatment progression offers a variety of benefits, including increased consistency, higher throughput and the automatic digitization of results.
The development of BacillAi was a hugely multidisciplinary project, requiring an expert team to overcome a series of technical challenges. These include:
- Developing a high-performance AI system that functions with sub-optimal images (such as low contrast) and that can be implemented on devices with limited computing power
- Designing an imaging system and phone mount that easily aligns the smartphone camera to the microscope optics and relays good images
- Developing an artificial sputum and culturing bacterial cells to create the large number of slides required to support AI training
- Bringing the system together for the user with an intuitive, user-friendly app interface and easy-to-assemble hardware
Cambridge Consultants works at the leading-edge of advances in AI, applying deep learning in applications including anomaly detection in telecommunications networks, self-driving cars, frictionless user interfaces and medical diagnosis and treatment. TB cell identification is particularly difficult due to the presence of other similar looking cells in sputum samples, variance in stain strength and variance in color between imaging devices. These conditions cause traditional, rule-defined computer vision techniques to fail, as they are unable to account for such breadth of data. By contrast, this rich, varied dataset creates the ideal conditions to train a robust and accurate deep learning system for cell identification.
Dr. Kathleen England, senior TB diagnostic advisor and formerly of Médecins Sans Frontières, commented: “The only monitoring tools we have today for assessing whether a TB patient’s treatment is working are AFB smear and culture, when available. The reading of slides requires training and highly-skilled microscopists, which are currently a limitation in many countries.
“A system that removes human variability in counting, reduces skill level, increases throughput and shares information via a network would be very beneficial for patient smear examination.”
Richard Hammond, Technology Director at Cambridge Consultants, commented: “Our team is focused on applying our deep learning expertise to real-world, high-impact challenges in healthcare. Today, we’ve demonstrated the feasibility of a deep learning-based system using practical and readily-available hardware components in the treatment of TB. Eventually we could see a platform like BacillAi assisting doctors to diagnose and monitor treatment for a host of conditions beyond TB in low-resource settings.”
BacillAi was developed using Cambridge Consultants’ purpose-built deep learning research facility. This laboratory implements NVIDIA DGX POD™ architecture using NetApp ONTAP AI, which provides petabyte-scale, high-performance, all-flash storage.
Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 850 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications. For more information, visit: www.cambridgeconsultants.com
Cambridge Consultants is part of Altran. Altran ranks as the undisputed global leader in Engineering and R&D services (ER&D). The company offers clients an unmatched value proposition to address their transformation and innovation needs. Altran works alongside its clients, from initial concept through industrialization, to invent the products and services of tomorrow. For over 35 years, the company has provided expertise in Automotive, Aeronautics, Space, Defense & Naval, Rail, Infra & Transport, Energy, Industrial & Consumer, Life Sciences, Communications, Semiconductor & Electronics, Software & Internet, Finance & Public Sector. The Aricent acquisition extends this leadership to semiconductor, digital experience and design innovation. Altran generated revenues of €2.9 billion in 2018, with some 47,000 employees in more than 30 countries.